25 September 2019

Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity

2019-09-25T15:17:16-07:00

*August 2019*  Science Immunology Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a first-line therapy for rapidly killing

Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity2019-09-25T15:17:16-07:00
6 July 2019

Video: Next Generation Sequencing for EGFR Mutant Lung Cancer: How it Guides Treatment Today & Tomorrow

2019-07-06T12:03:57-07:00

The EGFR Resisters hosted Dr. Josh Bauml for an extremely informative Facebook Live presentation on "Next Generation Sequencing for EGFR

Video: Next Generation Sequencing for EGFR Mutant Lung Cancer: How it Guides Treatment Today & Tomorrow2019-07-06T12:03:57-07:00
18 June 2019

High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients

2019-06-18T15:25:17-07:00

*January 2019*  Lung Cancer.   This small study from Taiwan was performed to investigate the relationship between PD-L1 expression levels and

High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients2019-06-18T15:25:17-07:00